⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Official Title: A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study ID: NCT00114166

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving topotecan in different dosing schedules may kill more tumor cells. PURPOSE: This phase II trial is studying how well topotecan works in treating patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Detailed Description: OBJECTIVES: Primary * Determine the antitumor activity of topotecan, in terms of frequency and duration of tumor response, in patients with recurrent platinum-sensitive ovarian epithelial, fallopian tube, or primary peritoneal cancer. * Determine the nature and degree of toxicity of this regimen in these patients. Secondary * Determine the duration of progression-free survival and overall survival in patients treated with these regimens. * Determine the effects of prognostic variables (i.e., initial performance status, age, and mucinous or clear cell histology) in patients treated with these regimens. OUTLINE: This is a multicenter study. Patients receive topotecan IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: Approximately 38-110 patients (19-55 per treatment arm) will be accrued for this study within 15-30 months.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States

George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States

Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States

CCOP - Christiana Care Health Services, Newark, Delaware, United States

Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia, United States

MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States

Rush-Copley Cancer Care Center, Aurora, Illinois, United States

University of Illinois Cancer Center, Chicago, Illinois, United States

Rush University Medical Center, Chicago, Illinois, United States

Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States

Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States

Advocate Lutheran General Cancer Care Center, Park Ridge, Illinois, United States

Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States

CCOP - Carle Cancer Center, Urbana, Illinois, United States

Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States

Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States

Woman's Hospital, Baton Rouge, Louisiana, United States

Union Hospital Cancer Program at Union Hospital, Elkton, Maryland, United States

Tufts-NEMC Cancer Center, Boston, Massachusetts, United States

UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States

Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States

CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States

Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States

Genesys Hurley Cancer Institute, Flint, Michigan, United States

Hurley Medical Center, Flint, Michigan, United States

Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States

Foote Memorial Hospital, Jackson, Michigan, United States

Borgess Medical Center, Kalamazoo, Michigan, United States

West Michigan Cancer Center, Kalamazoo, Michigan, United States

Bronson Methodist Hospital, Kalamazoo, Michigan, United States

Sparrow Regional Cancer Center, Lansing, Michigan, United States

St. Mary Mercy Hospital, Livonia, Michigan, United States

St. Joseph Mercy Oakland, Pontiac, Michigan, United States

Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States

William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States

Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States

St. John Macomb Hospital, Warren, Michigan, United States

University of Mississippi Cancer Clinic, Jackson, Mississippi, United States

Saint Louis University Cancer Center, Saint Louis, Missouri, United States

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States

CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States

St. John's Regional Health Center, Springfield, Missouri, United States

Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States

Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States

CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States

Methodist Estabrook Cancer Center, Omaha, Nebraska, United States

Jersey Shore Cancer Center at Jersey Shore University Medical Center, Neptune, New Jersey, United States

Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States

SUNY Downstate Medical Center, Brooklyn, New York, United States

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Stony Brook University Cancer Center, Stony Brook, New York, United States

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States

Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States

Mount Carmel Health - West Hospital, Columbus, Ohio, United States

Hillcrest Cancer Center at Hillcrest Hospital, Mayfield Heights, Ohio, United States

Lake/University Ireland Cancer Center, Mentor, Ohio, United States

Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States

Cancer Care Associates - Midtown Tulsa, Tulsa, Oklahoma, United States

Rosenfeld Cancer Center at Abington Memorial Hospital, Abington, Pennsylvania, United States

Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States

Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Cancer Center of Paoli Memorial Hospital, Paoli, Pennsylvania, United States

Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States

CCOP - MainLine Health, Wynnewood, Pennsylvania, United States

Lankenau Cancer Center at Lankenau Hospital, Wynnewood, Pennsylvania, United States

Avera Cancer Institute, Sioux Falls, South Dakota, United States

Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States

Harrington Cancer Center, Amarillo, Texas, United States

Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States

Marshfield Clinic - Indianhead Center, Rice Lake, Wisconsin, United States

Marshfield Clinic - Weston Center, Weston, Wisconsin, United States

Contact Details

Name: Thomas J. Herzog, MD

Affiliation: Herbert Irving Comprehensive Cancer Center

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: